<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657512</url>
  </required_header>
  <id_info>
    <org_study_id>1508030</org_study_id>
    <secondary_id>2015-001839-21</secondary_id>
    <secondary_id>140096A-21</secondary_id>
    <nct_id>NCT02657512</nct_id>
  </id_info>
  <brief_title>Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects</brief_title>
  <acronym>RICHAR</acronym>
  <official_title>Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects : RICHAR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X.
      Bleeding events related to rivaroxaban are the consequence of physiopathologic,
      pharmacokinetic issues or poisoning. Few results are available on the use of activated
      charcoal in rivaroxaban poisoning. Moreover, a recent study, in healthy subjects, shows that
      activated charcoal can reduce significantly exposition to apixaban (a direct oral
      anticoagulant of the same class). The objective of this study is to evaluate the effect of
      activated charcoal on rivaroxaban pharmacokinetics. It corresponds to a randomised open trial
      with an incomplete cross over design (3 occasions). It will enrol 12 healthy subjects. Four
      treatments modalities will be studied: rivaroxaban alone and rivaroxaban with activated
      charcoal administrated 2, 4 or 8 hours after rivaroxaban administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma concentrations of rivaroxaban</measure>
    <time_frame>H0.5, H0.75, H1, H1.5, H2, H2.5, H3, H4, H5, H6, H8, H10, H12, H14, H18 and H24 after rivaroxaban administration</time_frame>
    <description>rivaroxaban pharmacokinetics</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; rivaroxaban alone&quot;
Washout period (at least 6 days)
Period &quot; rivaroxaban and activated charcoal 2 hours after rivaroxaban administration&quot;
Washout period (at least 6 days)
Period &quot; &quot; rivaroxaban and activated charcoal 5 hours after rivaroxaban administration&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>. Period &quot; rivaroxaban and activated charcoal 5 hours after rivaroxaban administration&quot;
Washout period (at least 6 days)
Period &quot; rivaroxaban alone&quot;
Washout period (at least 6 days)
Period &quot; &quot; rivaroxaban and activated charcoal 8 hours after rivaroxaban administration&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>. Period &quot; rivaroxaban and activated charcoal 2 hours after rivaroxaban administration&quot;
Washout period (at least 6 days)
Period &quot; &quot; rivaroxaban and activated charcoal 8 hours after rivaroxaban administration&quot;
Washout period (at least 6 days)
Period &quot; rivaroxaban alone&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>rivaroxaban 40 mg/day (1 day)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban and activated charcoal</intervention_name>
    <description>rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  affiliated or beneficiary of a social security category

          -  having signed the inform consent form

          -  having signed the genetic consent form

          -  BMI between 18.5 and 25

          -  normal clinical exam

          -  normal biological exam

        Exclusion Criteria:

          -  contra-indication to rivaroxaban

          -  contra-indication to activated charcoal

          -  previous history of psychiatric disease, or antidepressant treatment, or convulsion,
             or hemorrhagic disease smoker

          -  Organic lesion likely to bleed

          -  severe liver disease

          -  severe kidney failure

          -  previous surgery within one month
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick MISMETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban, pharmacokinetics, activated charcoal, poisoning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

